NFKB1 and diabetes mellitus: Benfotiamine was previously verified to inhibit not only NADPH oxidase activity but also the pathways of PKC and thus block the activation of NF-κB in patients with diabetes, hence preventing NF-κB dependent signalling events such as the transcription of inflammatory cytokines, chemokines, as well as other inflammatory markers [13,36,46].